Get started
Author

Raymond W. Urbanski

Observed names: R. Urbanski, Ray Urbanski, Ray W. Urbanski, Raymond Urbanski, Raymond W Urbanski
OpenAlex ID: A5110079802
Evidence for a sympathoexcitatory pathway from the nucleus tractus solitarii to the ventrolateral medullary pressor area
1988 · Raymond W. Urbanski, Hreday N. Sapru · Journal of the Autonomic Nervous System · 110
Ventrolateral medullary pressor area: site of hypotensive action of clonidine
1987 · Susan Punnen, Raymond Urbanski, et al. · Brain Research · 107
Putative neurotransmitters involved in medullary cardiovascular regulation
1988 · Raymond W. Urbanski, Hreday N. Sapru · Journal of the Autonomic Nervous System · 99
Escherichia coli heat-stable enterotoxin receptors
1996 · Stephen L. Carrithers, Scott J. Parkinson, et al. · Diseases of the Colon & Rectum · 62
SURPASS-ET: phase III Study of Ropeginterferon Alfa-2b versus Anagrelide as Second-Line Therapy in Essential Thrombocythemia
2022 · Srdan Verstovsek, Norio Komatsu, et al. · Future Oncology · 39
Internalization of E. coli ST mediated by guanylyl cyclase C in T84 human colon carcinoma cells
1995 · R. Urbanski, S.L. Carrithers, et al. · Biochimica et Biophysica Acta (BBA) - General Subjects · 36
An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future
2023 · Albert Qin, Raymond W. Urbanski, et al. · Frontiers in Oncology · 33
PDF
A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera
2023 · Jie Jin, Lei Zhang, et al. · Experimental Hematology and Oncology · 32
PDF
Cardiovascular effects of substance P receptor stimulation in the ventrolateral medullary pressor and depressor areas
1989 · Raymond W. Urbanski, Jaya Murugaian, et al. · Brain Research · 16
Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera
2023 · Aaron T Gerds, Claudia Castro, et al. · Journal of Comparative Effectiveness Research · 6
Position paper: The time for cooperative group study of ropeginterferon alfa‐2b in young patients with myeloproliferative neoplasms is now
2023 · Nicole Kucine, Jewell A. Jessup, et al. · Pediatric Blood & Cancer · 5
MPN-545 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide as Second Line Therapy in Essential Thrombocythemia
2022 · Ruben Mesa, Norio Komatsu, et al. · Clinical Lymphoma Myeloma & Leukemia · 4
A Phase 3b, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft (P1101) in Adult Patients with Polycythemia Vera
2023 · John Mascarenhas, Tsewang Tashi, et al. · Blood · 3
MPN-546 A Single-Arm Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in North American Adults With Essential Thrombocythemia
2022 · Srdan Verstovsek, Ruben Mesa, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
Comparing Common Therapies in Polycythemia Vera (PV): A Disproportionality Analysis in the FDA Adverse Event Reporting System (FAERS) Database
2023 · Frank Snopek, Ali Seddighzadeh, et al. · Blood · 1
EXCEED-ET: A single-arm multicenter study to assess the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft (P1101) in North American adults with essential thrombocythemia.
2023 · Lucia Masarova, John Mascarenhas, et al. · Journal of Clinical Oncology · 1
Phase Ⅱ,Open-Label, Multicenter, Single-Arm Study Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Chinese Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea(HU)
2022 · Jie Jin, Lei Zhang, et al. · Blood · 1
Surpass-ET Trial: A Phase 3, Open-Label, Multicenter, Randomized, Active-Controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 Vs Anagrelide As Second Line Therapy for Essential Thrombocythemia
2021 · Ruben A. Mesa, Norio Komatsu, et al. · Blood · 1
POSTER: MPN-628 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs Anagrelide as Second Line Therapy in Essential Thrombocythemia
2023 · Lucia Masarova, Norio Komatsu, et al. · Clinical Lymphoma Myeloma & Leukemia
MPN-628 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs Anagrelide as Second Line Therapy in Essential Thrombocythemia
2023 · Lucia Masarova, Norio Komatsu, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: MPN-633 A Single-Arm Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in North American Adults With Essential Thrombocythemia
2023 · Lucia Masarova, John Mascarenhas, et al. · Clinical Lymphoma Myeloma & Leukemia
MPN-633 A Single-Arm Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in North American Adults With Essential Thrombocythemia
2023 · Lucia Masarova, John Mascarenhas, et al. · Clinical Lymphoma Myeloma & Leukemia
A Phase 3b, Single-Arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon Alfa-2b-Njft (P1101) in Adult Patients with Polycythemia Vera
2022 · John Mascarenhas, Oleh Zagrijtschuk, et al. · Blood
Poster: MPN-546 A Single-Arm Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in North American Adults With Essential Thrombocythemia
2022 · Srdan Verstovsek, Ruben Mesa, et al. · Clinical Lymphoma Myeloma & Leukemia
Poster: MPN-545 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide as Second Line Therapy in Essential Thrombocythemia
2022 · Ruben Mesa, Norio Komatsu, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 27
Citation count: 558
H-index: 9
I10-index: 9
Year
Topic
Type